Psilocybin vs. Ketamine Therapy: What Research Actually Says

Two Different Substances, Two Different Approaches

It helps to start with what each substance actually is, because the comparison gets muddy quickly when people treat them as interchangeable alternatives. They are not.

Ketamine is a synthetic dissociative anesthetic developed in 1962. It has been used safely in hospitals and emergency medicine for decades. In mental health contexts, it is typically administered by IV infusion or, in the case of esketamine (brand name Spravato), as a nasal spray. Ketamine primarily works by blocking NMDA receptors in the brain’s glutamate system. This action promotes neuroplasticity, the formation of new synaptic connections, and can produce significant relief from depressive symptoms within hours of a single session. The experience itself is dissociative: patients often describe a sense of detachment from the body and surroundings, sometimes accompanied by perceptual shifts. Sessions typically last 40 to 60 minutes.

Psilocybin is a naturally occurring compound found in certain fungi. Once ingested, it converts to psilocin in the body, which acts primarily on serotonin receptors (specifically 5-HT2A receptors). Rather than dissociation, psilocybin tends to produce profound alterations in perception, emotion, and sense of self. Sessions are considerably longer: most people feel effects for four to six hours. The therapeutic model centers heavily on the subjective experience itself, with integration work done afterward to translate insights into lasting change. Both substances promote neuroplasticity, though through distinct pharmacological pathways.

What the Research Shows for Psilocybin vs. Ketamine Depression Treatment

Both substances have meaningful clinical evidence behind them for depression, and a 2024 network meta-analysis published in Psychiatry and Clinical Neurosciences Reports found that both IV ketamine and psilocybin showed significantly greater antidepressant effects compared to other interventions, with no significant differences in tolerability between the two. That is a useful baseline: at the population level, they appear comparably effective for depression, with different durability profiles.

Ketamine’s primary clinical advantage is speed. Symptom relief can begin within hours to days of an infusion. This makes it particularly valuable in acute situations, including when suicidal ideation is a factor. The limitation is durability: effects from a single session often begin to fade within one to two weeks, which is why clinical protocols typically involve repeated infusions. Maintenance sessions are common for people who respond well.

Psilocybin’s evidence base is smaller but points toward a different pattern. Research published in Frontiers in Psychiatry (2024) noted that depressive symptoms can be rapidly and substantially reduced with psilocybin, and studies suggest these effects may persist for months following a single or small number of sessions. The COMPASS Pathways Phase 3 program, reading out through 2025 and 2026, has reported positive results in treatment-resistant depression, with a potential FDA submission targeted for late 2026. This research trajectory matters for anyone considering psilocybin: it is not fringe science, but it is also not yet at the approval stage.

For conditions beyond depression, the picture is also nuanced. Ketamine has been studied for chronic pain, PTSD, and anxiety, and has an established record in off-label clinical use. Psilocybin has shown particular promise for end-of-life existential distress, treatment-resistant depression, addiction, and obsessive-compulsive disorder, though most of these indications are still at clinical trial stage.

Legal Status: The Practical Difference That Shapes Everything

On the question of access, the two substances are not in the same position at all, and this is where the comparison becomes most consequential for someone making a real decision right now.

Ketamine is a Schedule III controlled substance in the United States, meaning it is legal when prescribed by a licensed provider. Esketamine (Spravato) received FDA approval in 2019 specifically for treatment-resistant depression and is administered under clinical supervision. IV ketamine infusions are used off-label for depression, PTSD, and anxiety across all 50 states, and telehealth prescribing flexibilities extended through December 2026 have expanded access further. Insurance coverage for esketamine is available through some plans, including Medicare. IV infusions typically run $400 to $800 per session out of pocket.

Psilocybin remains a Schedule I substance under federal law, with no FDA approval for any indication as of this writing. Legal access to supervised psilocybin therapy currently exists in Oregon (since 2023), Colorado (since 2025), and New Mexico (since April 2025). In April 2026, President Trump signed an executive order directing the FDA and DEA to accelerate research and review of psilocybin and other psychedelics for mental health treatment, signaling continued federal-level momentum. Outside of those three states, access is limited to clinical trials. Costs for legal psilocybin sessions run $500 to $3,400 out of pocket, with no insurance coverage available because FDA approval has not yet been granted.

If you are not in Oregon, Colorado, or New Mexico and you are not enrolled in a clinical trial, psilocybin therapy through legitimate legal channels is not currently available to you in the United States. That is not a judgment about the substance’s value; it is the regulatory reality as of mid-2026.

Safety Profiles and Contraindications

Both substances have favorable safety records when administered in properly supervised clinical settings, and both carry risks that require serious screening.

Ketamine’s most common acute side effects include elevated blood pressure, heart rate changes, nausea, dizziness, and dissociation. These are typically monitored and managed within the clinical session. The more significant concerns arise from longer-term or frequent use without oversight: potential for psychological dependence, bladder complications (particularly with high-dose recreational use), and cognitive effects. Ketamine is contraindicated for people with uncontrolled hypertension, active psychosis, or certain cardiovascular conditions. Because it elevates heart rate and blood pressure during sessions, it requires medical monitoring even at therapeutic doses.

Psilocybin has very low physiological toxicity. There are no documented cases of fatal overdose from psilocybin alone in humans, and it is considered non-addictive. Physical side effects during sessions can include nausea, elevated heart rate and blood pressure, and headache. The primary risks are psychological: difficult experiences, acute anxiety, and in rare cases, the triggering of prolonged psychotic episodes in individuals with predisposing conditions. This is why psilocybin is contraindicated for anyone with a personal or family history of psychotic disorders, active untreated bipolar disorder, and certain cardiovascular conditions. It should not be combined with SSRIs or lithium. A systematic review published in Psychiatry and Clinical Neurosciences Reports (2024) found no significant differences between psilocybin and ketamine in terms of tolerability and acceptability relative to placebo, which is encouraging but does not eliminate the need for careful screening.

If you want a thorough breakdown of who should not pursue psychedelic therapy, our guide on Contraindications for Psychedelic Therapy covers both substances in detail. Screening is not optional. For either modality, the safety of the experience depends significantly on what happens before it.

The Experience Itself: What to Expect

The subjective difference between a ketamine session and a psilocybin session is significant, and it matters for fit.

Ketamine is often described as creating a temporary sense of separation from ordinary reality, sometimes accompanied by visual or sensory distortions, a feeling of floating, or an altered relationship to thoughts and memories. Sessions are shorter (typically under an hour) and the clinical environment tends to be medical in structure. For many people, especially those looking for relief rather than a deeply introspective experience, ketamine’s more contained format is a better fit.

A psilocybin session is longer, more immersive, and tends to involve more direct engagement with emotions, memories, and psychological material. The therapeutic model expects this: the experience is not incidental to the treatment, it is central to it. This is why the preparation and integration phases matter so much in psilocybin-assisted therapy, and why working with a qualified guide is not a luxury but a clinical necessity. For people who want to engage deeply with psychological patterns and are prepared for an intense experience, psilocybin’s profile may be more aligned with those goals.

Neither is a passive intervention. Both require preparation, appropriate set and setting, and professional support. The question of which psychedelic therapy is right for you is, at its core, a question about what you need, what is available to you, and whether you are an appropriate candidate for either.

Cost and Access: A Realistic Summary

Ketamine therapy is accessible right now, across all 50 states, through licensed medical providers. Costs vary: esketamine nasal spray may be covered by insurance, while IV infusions are typically $400 to $800 per session, with most protocols involving six sessions in the initial phase. Psilocybin therapy through legal channels is available in three states, at out-of-pocket costs ranging from $500 to over $3,000 per session, with no insurance coverage. Clinical trials remain an option for eligible individuals and are often free to participants.

The cost difference is real, and so is the geographic limitation. These are factors that deserve honest consideration alongside the clinical evidence when weighing psilocybin vs. ketamine therapy.